Mission Wealth Management LP Boosts Holdings in Zoetis Inc. (NYSE:ZTS)

Mission Wealth Management LP boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 132.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,825 shares of the company's stock after acquiring an additional 3,887 shares during the period. Mission Wealth Management LP's holdings in Zoetis were worth $1,124,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ZTS. HUB Investment Partners LLC raised its holdings in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC increased its stake in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the last quarter. Deseret Mutual Benefit Administrators grew its stake in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after buying an additional 65 shares during the period. Lindbrook Capital LLC increased its stake in Zoetis by 1.8% during the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock worth $595,000 after acquiring an additional 65 shares during the last quarter. Finally, Ironwood Investment Management LLC increased its position in shares of Zoetis by 0.8% in the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock worth $1,361,000 after acquiring an additional 68 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Down 1.7%

Shares of Zoetis stock opened at $161.63 on Wednesday. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock has a market capitalization of $71.96 billion, a P/E ratio of 29.02, a PEG ratio of 2.73 and a beta of 0.94. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The stock has a 50 day moving average price of $159.23 and a two-hundred day moving average price of $163.74.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business posted $1.38 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.24%. Zoetis's dividend payout ratio is 35.91%.

Analysts Set New Price Targets

ZTS has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Piper Sandler boosted their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Finally, Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $212.75.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.